Fc and complement receptors on malignant tumor cells

Abstract

The Fc-C'-receptor-positive cells were investigated in tumor cell suspensions from 196 malignant tumors. The number of EA (Fc) and EAC' (C') rosettes was determined; the rosetteforming cells were identified cytologically, the cell suspensions were exposed to carbon particles, and they were grown in tissue culture. The results suggest that Fc or C' receptors might be present in malignant tumor cells as well as in host defense (inflammatory) cells invading the tumor.Cancer 48 pensions to carbon particles in order to functionally identify the macrophages. The results suggest that there are Fc or C' receptors in the surface membrane of malignant tumor cells other than those found in malignant lymphoma or leukemia. Materials a n d MethodsCell suspensions from 196 malignant tumors were prepared from fresh intraoperatively obtained tumor tissue. The cells were collected in TNG (tris-NaC1-glucose, p H 7.3; Merck, Darmstadt) which was supplemented by I mg DNAse (Boehringer, Mannheim). After centrifugation, the pellet was resuspended in 10 ml red blood cell remover, centrifuged, and resuspended in TNG.The red blood cell remover was composed of three solutions designated A, B, and C. Solution A consisted of 35.0 g of NH4CI; 1.85 g of KCl; 1.550 g of NaHPO, x 2 H,O; 0.119 g of KH,PO,; 5.0 g of glucose; 0.05 g of phenolrot -+ ad 1000 ml of aqua tridest. Solution B consisted of 0.42 g of MgC& x 6 H 2 0 ; 0.14 g of MgSO, x 7 H,O .+ ad 1000 ml of aqua tridest. Solution C consisted of 2.25 g of NaHCO, + ad 100 ml of aqua tridest. The red blood cell remover was made up of 2 ml of solution A, 0.5 ml of solution B, and 0.5 ml of solution C + ad 10 ml aqua tridest. TNG contains 15% fetal calf serum (FCS) (Flow) and 0.2 mg of DNAse. The number of cells was adjusted to 1 x 106/ml 15% TNG-FCS-DNAse.Preparation of Assay Cells for Fc Receptor (EA)J First, 250 pl of sheep red blood cells (SRBC) were suspended in 1 ml of PBS (pH, 7.2) and 1 ml of 0.1%

Morphologic, cytochemical and neurochemical characterization of the human medulloblastoma cell line TE671

“…Complement receptors have been described on endodermal, mesodermal, and neuroectodermal derived tumor cells (39,40). In contrast to the loss of complement receptors in these short term explants in vitro (39), TE671 in long-term culture maintained the expression of a C3b receptor. This finding suggests that complement receptors could be a stable characteristic of some medulloblastoma tumor cells in vivo.…”

“…Since Sudan black B, and a-naphtyl esterase stains were negative, a myeloid or histocytic origin, such as from microglia, was less likely. Complement receptors have been described on endodermal, mesodermal, and neuroectodermal derived tumor cells (39,40). In contrast to the loss of complement receptors in these short term explants in vitro (39), TE671 in long-term culture maintained the expression of a C3b receptor.…”

Metastatic Melanomas Express Inhibitory Low Affinity Fc Gamma Receptor and Escape Humoral Immunity

“…At the same time, Isaac Witz showed the presence of IgG within non-lymphoid tumor tissue and observed that these IgG did not exhibit any antibody activity against tumor antigens, suggesting that they bound to tumor cells via their Fc region [50]. This hypothesis was supported by further experiments where primary cultures of tumors and SRBC formed rosettes [51, 52]. In addition, it was observed that tumor cells injected in mice immunized with non-tumoral antigens were able to bind antibody via their Fc region [53].…”

Fc γ receptors

“…However, the ectopic expression of Fc␥Rs by non-hematopoïetic tumor cells was a controversy because of the presence of Fc␥R positive inflammatory cells at the tumor site [48] and because Fc␥R expression was lost during short-term culture of tumor cells in vitro [49]. We reinvestigated the expression of Fc␥Rs on human tumor cells of non-hematopoïetic origin.…”